JPH09501826A - 新規な弱毒化シュードモナス・エルギノーザ株 - Google Patents
新規な弱毒化シュードモナス・エルギノーザ株Info
- Publication number
- JPH09501826A JPH09501826A JP7501593A JP50159395A JPH09501826A JP H09501826 A JPH09501826 A JP H09501826A JP 7501593 A JP7501593 A JP 7501593A JP 50159395 A JP50159395 A JP 50159395A JP H09501826 A JPH09501826 A JP H09501826A
- Authority
- JP
- Japan
- Prior art keywords
- cfcpa
- pseudomonas aeruginosa
- kccm
- strain
- culture collection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000589517 Pseudomonas aeruginosa Species 0.000 title claims abstract description 183
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 101
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 113
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 112
- 210000002421 cell wall Anatomy 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 64
- 229960005486 vaccine Drugs 0.000 claims abstract description 62
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 59
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 59
- 208000032536 Pseudomonas Infections Diseases 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 27
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 229940072221 immunoglobulins Drugs 0.000 claims abstract description 16
- 230000003053 immunization Effects 0.000 claims abstract description 15
- 238000010171 animal model Methods 0.000 claims abstract description 14
- 238000002649 immunization Methods 0.000 claims abstract description 13
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 11
- 230000001939 inductive effect Effects 0.000 claims abstract description 3
- 241000589516 Pseudomonas Species 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 39
- 208000015181 infectious disease Diseases 0.000 claims description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- 239000002609 medium Substances 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 230000036039 immunity Effects 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 238000011534 incubation Methods 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- 239000008055 phosphate buffer solution Substances 0.000 claims description 16
- 244000068988 Glycine max Species 0.000 claims description 15
- 235000010469 Glycine max Nutrition 0.000 claims description 15
- 102000004142 Trypsin Human genes 0.000 claims description 15
- 108090000631 Trypsin Proteins 0.000 claims description 15
- 239000012588 trypsin Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002158 endotoxin Substances 0.000 claims description 8
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 241000256215 Spongomorpha aeruginosa Species 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000001888 Peptone Substances 0.000 claims description 5
- 108010080698 Peptones Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 235000019319 peptone Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 238000005273 aeration Methods 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 102000005548 Hexokinase Human genes 0.000 claims description 3
- 108700040460 Hexokinases Proteins 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 244000062789 Rhododendron indicum Species 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 abstract description 98
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 235000004252 protein component Nutrition 0.000 abstract description 3
- 238000007670 refining Methods 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 230000000813 microbial effect Effects 0.000 description 17
- 244000005700 microbiome Species 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 15
- 238000000746 purification Methods 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 230000001681 protective effect Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 230000003449 preventive effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 241000108056 Monas Species 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000012460 protein solution Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000001147 anti-toxic effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229940021993 prophylactic vaccine Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000661938 Capsus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000975394 Evechinus chloroticus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000069157 Miconia aeruginosa Species 0.000 description 1
- 231100000757 Microbial toxin Toxicity 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 108700027479 Syntex adjuvant formulation Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910000336 copper(I) sulfate Inorganic materials 0.000 description 1
- WIVXEZIMDUGYRW-UHFFFAOYSA-L copper(i) sulfate Chemical compound [Cu+].[Cu+].[O-]S([O-])(=O)=O WIVXEZIMDUGYRW-UHFFFAOYSA-L 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- OVJOMRKANUZJBM-UHFFFAOYSA-L lead(2+);sulfite Chemical compound [Pb+2].[O-]S([O-])=O OVJOMRKANUZJBM-UHFFFAOYSA-L 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.マウスでのLD50が少なくとも2.0×107細胞である弱毒化シュードモナス・ エルギノーザ株であって、シュードモナス・エルギノーザに感染している患者か ら免疫タイプに従って純粋状態でシュードモナス・エルギノーザを単離する工程 、そして該単離した株を繰り返し精製して該株を弱毒化する工程により得られる 弱毒化シュードモナス・エルギノーザ株。 2.Korean Federation of Culture Collection 受託番号KCCM 10029(CFCPA 1 0142)を有する、請求項1に記載のシュードモナス・エルギノーザ株。 3.Korean Federation of Culture Collection 受託番号KCCM 10030(CFCPA 2 0215)を有する、請求項1に記載のシュードモナス・エルギノーザ株。 4.Korean Federation of Culture Collection 受託番号KCCM 10031(CFCPA 3 0720)を有する、請求項1に記載のシュードモナス・エルギノーザ株。 5.Korean Federation of Culture Collection 受託番号KCCM 10032(CFCPA 4 0057)を有する、請求項1に記載のシュードモナス・エルギノーザ株。 6.Korean Federation of Culture Collection 受託番号KCCM 10033(CFCPA 5 0243)を有する、請求項1に記載のシュードモナス・エルギノーザ株。 7.Korean Federation of Culture Collection 受託番号KCCM 10034(CFCPA 6 0534)を有する、請求項1に記載のシュードモナス・エルギノーザ株。 8.Korean Federation of Culture Collection 受託番号KCCM 10035(CFCPA 7 0018)を有する、請求項1に記載のシュードモナス・エルギノーザ株。 9.シュードモナス・エルギノーザ感染に対する免疫化のためのワクチンの調 製のための、以下の: Korean Federation of Culture Collection 受託番号KCCM 10029(CFCPA 10142 )、 Korean Federation of Culture Collection 受託番号KCCM 10030(CFCPA 20215 )、 Korean Federation of Culture Collection 受託番号KCCM 10031(CFCPA 30720 )、 Korean Federation of Culture Collection 受託番号KCCM 10032(CFCPA 40057 )、 Korean Federation of Culture Collection 受託番号KCCM 10033(CFCPA 50243)、 Korean Federation of Culture Collection 受託番号KCCM 10034(CFCPA 60534 )、および Korean Federation of Culture Collection 受託番号KCCM 10035(CFCPA 70018 ) からなる群から選択される、少なくとも1株のシュードモナス・エルギノーザ株 の使用。 10.シュードモナス・エルギノーザにより引き起こされる疾患に対して免疫 化する方法であって、該方法は、 Korean Federation of Culture Collection 受託番号KCCM 10029(CFCPA 10142 )、 Korean Federation of Culture Collection 受託番号KCCM 10030(CFCPA 20215 )、 Korean Federation of Culture Collection 受託番号KCCM 10031(CFCPA 30720 )、 Korean Federation of Culture Collection 受託番号KCCM 10032(CFCPA 40057 )、 Korean Federation of Culture Collection 受託番号KCCM 10033(CFCPA 50243 )、 Korean Federation of Culture Collection 受託番号KCCM 10034(CFCPA 60534 )、および Korean Federation of Culture Collection 受託番号KCCM 10035(CFCPA 70018 ) からなる群から選択される、少なくとも1つの弱毒化非病原性シュードモナス・ エルギノーザ由来の細胞壁タンパク質の混合物を含有する非病原性抗原を、シュ ードモナス・エルギノーザにより引き起こされる疾患を防ぐように免疫応答をヒ ト中で誘発するのに十分な量で免疫化を必要とする該ヒトに注入する方法。 11.弱毒化シュードモナス・エルギノーザ株由来の前記細胞壁タンパク質が 、10,000〜100,000の範囲の分子量を有する、請求項10に記載の方法。 12.前記細胞壁タンパク質が筋肉内注射により投与される、請求項10に記 載の方法。 13.シュードモナス・エルギノーザにより引き起こされる疾患に対して免疫 応答を誘発するための非病原性ワクチンであって、該ワクチンは、シュードモナ ス・エルギノーザにより引き起こされる疾患を防ぐために免疫応答を誘発し、以 下の Korean Federation of Culture Collection 受託番号KCCM 10029(CFCPA 10142 )、 Korean Federation of Culture Collection 受託番号KCCM 10030(CFCPA 20215 )、 Korean Federation of Culture Collection 受託番号KCCM 10031(CFCPA 30720 )、 Korean Federation of Culture Collection 受託番号KCCM 10032(CFCPA 40057 )、 Korean Federation of Culture Collection 受託番号KCCM 10033(CFCPA 50243 )、 Korean Federation of Culture Collection 受託番号KCCM 10034(CFCPA 60534 )、および Korean Federation of Culture Collection 受託番号KCCM 10035(CFCPA 70018 ) からなる群から選択される、少なくとも1つの弱毒化シュードモナス・エルギノ ーザ株由来の細胞壁タンパク質の混合物を包含する、ワクチン。 14.前記弱毒化シュードモナス・エルギノーザ株が、CFCPA 10142、CFCPA 2O215、CFCPA 30720、CFCPA 40057、CFCPA 50243、CFCPA 60534、およびCFCPA 7 0018からなる群から選択される少なくとも3つの株を包含する、請求項13に記 載のワクチン。 15.前記弱毒化シュードモナス・エルギノーザ株が、CFCPA 10142、CFCPA 2 0215、およびCFCPA 30720からなる、請求項14に記載のワクチン。 16.前記弱毒化シュードモナス・エルギノーザ株が、CFCPA 10142、CFCPA 2 0215、CFCPA 30720、および、CFCPA 6053 4からなる群から選択される、請求項14に記載のワクチン。 17.前記弱毒化シュードモナス・エルギノーザ株が、CFCPA 10142、CFCPA 2 0215、CFCPA 30720、CFCPA 40057、CFCPA 50243、CFCPA 60534、およびCFCPA 70 018の7タイプである、請求項14に記載のワクチン。 18.前記弱毒化シュードモナス・エルギノーザのそれぞれ由来の前記細胞壁 タンパク質が、等量で存在する、請求項13〜17のいずれかに記載のワクチン 。 19.薬学的受容可能賦形剤をさらに含有する、請求項13に記載のワクチン 。 20.シュードモナス・エルギノーザ感染症に対する免疫化のための非病原性 ワクチンの調製方法であって、以下の工程: a)シュードモナス・エルギノーザに感染している患者からシュードモナス・ エルギノーザを集める工程; b)純粋状態において少なくとも1種のシュードモナス・エルギノーザを選択 し単離する工程; c)純粋な単離されたそれぞれのシュードモナス・エルギノーザを、第1培養 培地中でインキュベートする工程; d)それぞれの純粋なインキュベートした株を実験動物中 に注入することにより弱毒化し、そしてそれぞれの弱毒化シュードモナス・エル ギノーザ株から最も弱毒化された株を選択する工程; e)それぞれの弱毒化シュードモナス・エルギノーザ株を、第2培養培地中で インキュベートする工程; f)該培養培地から該弱毒化シュードモナス・エルギノーザを分離する工程; g)該分離したシュードモナス・エルギノーザを、有機溶媒で処理して細胞壁 脂質成分を不活性化し除去する工程; h)該シュードモナス・エルギノーザの細胞が破壊されているか否かを、細胞 質マーカー酵素である乳酸デヒドロゲナーゼ、またはヘキソキナーゼの存在を確 認することにより同時に測定しながら、該処理したシュードモナス・エルギノー ザから該細胞壁タンパク質を抽出する工程; i)該抽出した細胞壁タンパク質を限外濾過して、10,000〜100,000の範囲の 分子量を有する細胞壁タンパク質のみを選択する工程; j)該細胞壁タンパク質を超遠心分離して、あらゆるリポ多糖およびあらゆる 細菌性物質をさらに除去する工程; k)該選択した細胞壁タンパク質を、純粋状態で回収する工程;および l)該選択した細胞壁タンパク質を抗原性物質として使用して免疫化を誘発し 、ワクチンを調製する工程、 を包含する、方法。 21.前記抽出が、前記処理したシュードモナス・エルギノーザ細胞を緩衝溶 液に入れることにより行われる、請求項20に記載の方法。 22.前記緩衝溶液が、リン酸緩衝溶液およびトリス緩衝溶液からなる群から 選択される、請求項21に記載の方法。 23.前記細胞壁タンパク質の抽出を、細菌塊を、または前記処理したシュー ドモナス・エルギノーザ細胞を、ミキサーまたはホモジナイザーにかけて行う、 請求項20に記載の方法。 24.前記ミキサーが、4℃で、100〜2000rpmで行われる、請求項23に記載 の方法。 25.前記抽出が5〜6回行われる、請求項20に記載の方法。 26.前記有機溶媒が、アセトン、クロロホルム、エタノール、ブタノールか らなる群から選択され、そして最も好ましくは、有機溶媒がアセトンである、請 求項20に記載の方法。 27.前記単離されたシュードモナス・エルギノーザ株が、 CFCPA 10142、CFCPA 20215、CFCPA 30720、CFCPA 40057、CFCPA 50243、CFCPA 6 0534、およびCFCPA 70018を包含する、請求項20に記載の方法。 28.前記第2の培養培地が、ダイズトリプシンブロス、およびグルコース(3 0g/l)、ペプトン(15g/l)、MgSO4(0.5g/l)、CaCO3(5g/l)、KH2PO4(1g/l)、FeSO4 (5mg/l)、CuSO4(5mg/l)、およびZnSO4(5mg/l)を含有する培養培地からなる 群から選択される、請求項20に記載の方法。 29.前記弱毒化シュードモナス・エルギノーザのインキュベーション条件が 、37℃の温度、通気率1vvm(体積/体積・分)、および培養培地溶液の5%v/vの 接種体積を包含し、インキュベーションが、最初の2時間は100rpm、続く10〜20 時間、好ましくは12〜16時間は600rpmのの撹拌速度下で行われる、請求項20に 記載の方法。 30.1リットル当たりグルコース30g、ペプトン15g,MgSO4 0.5g、CaCO3 5g、KH2PO4 1g、FeSO4 5mg、CuSO4 5mg、およびZnSO4 5mgを含有する、 弱毒化シュードモナス・エルギノーザをインキュベートするためのインキュベー ション培地であって、該シュードモナス・エルギノーザは、 Korean Federation of Culture Collection 受託番号KCCM 10029(CFCPA 10142 )、 Korean Federation of Culture Collection 受託番号KCCM 10030(CFCPA 20215 )、 Korean Federation of Culture Collection 受託番号KCCM 10031(CFCPA 30720 )、 Korean Federation of Culture Collection 受託番号KCCM 10032(CFCPA 40057 )、 Korean Federation of Culture Collection 受託番号KCCM 10033(CFCPA 50243 )、 Korean Federation of Culture Collection 受託番号KCCM 10034(CFCPA 60534 )、および Korean Federation of Culture Collection 受託番号KCCM 10035(CFCPA 70018 ) からなる群から選択される、インキュベーション培地。 31.感染症を発現している患者におけるシュードモナス・エルギノーザ感染 症を治療するための治療剤であって、該治療剤が少なくとも1つのシュードモナ ス・エルギノーザ株に対して特異的な少なくとも1つの免疫グロブリンを含有し 、ここで、該免疫グロブリンは、 Korean Federation of Culture Collection 受託番号KCCM 10029(CFCPA 10142 )、 Korean Federation of Culture Collection 受託番号KCCM 10030(CFCPA 20215 )、 Korean Federation of Culture Collection 受託番号KCCM 10031(CFCPA 30720)、 Korean Federation of Culture Collection 受託番号KCCM 10032(CFCPA 40057 )、 Korean Federation of Culture Collection 受託番号KCCM 10033(CFCPA 50243 )、 Korean Federation of Culture Collection 受託番号KCCM 10034(CFCPA 60534 )、および Korean Federation of Culture Collection 受託番号KCCM 10035(CFCPA 70018 ) からなる群から選択される少なくとも1つの弱毒化シュードモナス・エルギノー ザ株由来の細胞壁タンパク質を、該免疫グロブリンの産生を引き起こし、次いで シュードモナス・エルギノーザにより引き起こされる疾患の不利な影響が減少す るような免疫応答を該宿主中に誘発するのに十分な量を、好適な宿主に注入する ことにより誘発された、免疫グロブリンである、治療剤。 32.それぞれFisher免疫タイプ1、2、3、4、5、6、および7に相当す るシュードモナス・エルギノーザ株に対する免疫グロブリンを含有する、請求項 31に記載の治療剤。 33.Fisher免疫タイプ1、2、3、4、5、6、および7に相当するいずれ か4つのシュードモナス・エルギノーザ株に対する免疫グロブリンを含有する、 請求項31に記載の治 療剤。 34.Fisher免疫タイプ1、2、3、4、5、6、および7に相当するいずれ か3つのシュードモナス・エルギノーザ株に対する免疫グロブリンを含有する、 請求項31に記載の治療剤。 35.凍結乾燥形態である、請求項31に記載の治療剤。 36.マンニトール、ラクトース、サッカロース、およびヒトアルブミンから なる群から選択される、適切な薬学的受容可能な担体をさらに包含する、請求項 35に記載の治療剤。 37.適切な薬学的に受容可能な担体をさらに包含する、請求項31に記載の 液状の治療剤。 38.注射、錠剤、カプセル、点眼薬、噴霧薬、または軟膏の形態で薬学的に 投与される形に調製された、請求項31に記載の治療剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930010273A KR960014620B1 (ko) | 1993-06-07 | 1993-06-07 | 신규한 약독화 녹농균 및 그를 이용한 녹농균 감염 예방 백신 |
KR1993/10281 | 1993-06-07 | ||
KR1019930010281A KR970001710B1 (ko) | 1993-06-07 | 1993-06-07 | 녹농균 감염증 치료제 및 그의 제조방법 |
KR1993/10273 | 1993-06-07 | ||
PCT/KR1994/000062 WO1994028928A1 (en) | 1993-06-07 | 1994-06-02 | Novel attenuated pseudomonas aeruginosa strains |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09501826A true JPH09501826A (ja) | 1997-02-25 |
JP2911603B2 JP2911603B2 (ja) | 1999-06-23 |
Family
ID=26629705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7501593A Expired - Fee Related JP2911603B2 (ja) | 1993-06-07 | 1994-06-02 | 新規な弱毒化シュードモナス・エルギノーザ株 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0702564B1 (ja) |
JP (1) | JP2911603B2 (ja) |
CN (1) | CN1112356A (ja) |
AT (1) | AT408445B (ja) |
AU (1) | AU676575B2 (ja) |
CA (1) | CA2141871C (ja) |
CH (1) | CH687233A5 (ja) |
DE (3) | DE4447677C2 (ja) |
ES (1) | ES2074968B1 (ja) |
GB (1) | GB2285925B (ja) |
NL (1) | NL194910C (ja) |
NO (1) | NO317148B1 (ja) |
RU (1) | RU2155226C2 (ja) |
SE (1) | SE507114C2 (ja) |
TW (1) | TW403655B (ja) |
WO (1) | WO1994028928A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1086588C (zh) * | 1995-12-07 | 2002-06-26 | 余国华 | 假单胞菌活性蛋白及其生产方法 |
CN1328371C (zh) * | 2005-09-01 | 2007-07-25 | 北京未名凯拓农业生物技术有限公司 | 一株铜绿假单胞菌及其培养方法与应用 |
CN102534027A (zh) * | 2012-02-14 | 2012-07-04 | 上海中优医药高科技有限公司 | MDRPA中QacEΔ1基因的检测引物及其检测方法 |
CN102534029A (zh) * | 2012-02-14 | 2012-07-04 | 上海中优医药高科技有限公司 | MRSA中QacB基因的检测引物及其检测方法 |
IT201600091033A1 (it) * | 2016-09-08 | 2018-03-08 | Bioimmunizer Sagl | Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti. |
CN109401992B (zh) * | 2017-08-18 | 2021-07-23 | 黑龙江省科学院微生物研究所 | 一株高产内毒素蛋白的铜绿假单胞菌及其应用 |
CN110724647B (zh) * | 2018-07-17 | 2022-11-04 | 黑龙江省科学院微生物研究所 | 一株所产内毒素蛋白对7种血清型菌株具有免疫保护作用的铜绿假单胞菌及其应用 |
WO2021031270A1 (zh) * | 2019-08-22 | 2021-02-25 | 四川大学 | 细菌膜囊泡及其分离制备系统和方法 |
CN114763544A (zh) * | 2021-01-15 | 2022-07-19 | 黑龙江省科学院微生物研究所 | 一种铜绿假单胞菌高产蛋白菌株的生物诱变方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3987164A (en) * | 1970-10-20 | 1976-10-19 | Yuzuru Homma | Method for prevention of pseudomonas aeruginosa infections |
US3928565A (en) * | 1971-10-19 | 1975-12-23 | Yuzuru Homma | Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties |
JPS5612435B1 (ja) * | 1971-03-29 | 1981-03-20 | ||
DE3829616C2 (de) * | 1988-09-01 | 1996-08-29 | Behringwerke Ag | Lipoprotein I (OMPI) von Pseudomonas aeruginosa |
-
1994
- 1994-06-02 GB GB9502373A patent/GB2285925B/en not_active Expired - Fee Related
- 1994-06-02 EP EP94917176A patent/EP0702564B1/en not_active Expired - Lifetime
- 1994-06-02 CH CH00454/95A patent/CH687233A5/de not_active IP Right Cessation
- 1994-06-02 DE DE4447677A patent/DE4447677C2/de not_active Expired - Fee Related
- 1994-06-02 AU AU68571/94A patent/AU676575B2/en not_active Ceased
- 1994-06-02 CN CN94190491A patent/CN1112356A/zh active Pending
- 1994-06-02 ES ES09550003A patent/ES2074968B1/es not_active Expired - Fee Related
- 1994-06-02 DE DE4493997A patent/DE4493997C2/de not_active Expired - Fee Related
- 1994-06-02 CA CA002141871A patent/CA2141871C/en not_active Expired - Fee Related
- 1994-06-02 RU RU95113158/13A patent/RU2155226C2/ru not_active IP Right Cessation
- 1994-06-02 AT AT0900694A patent/AT408445B/de not_active IP Right Cessation
- 1994-06-02 DE DE4493997T patent/DE4493997T1/de active Pending
- 1994-06-02 WO PCT/KR1994/000062 patent/WO1994028928A1/en active IP Right Grant
- 1994-06-02 JP JP7501593A patent/JP2911603B2/ja not_active Expired - Fee Related
- 1994-06-02 NL NL9420005A patent/NL194910C/nl not_active IP Right Cessation
- 1994-06-04 TW TW083105105A patent/TW403655B/zh not_active IP Right Cessation
-
1995
- 1995-02-06 NO NO19950421A patent/NO317148B1/no not_active IP Right Cessation
- 1995-02-06 SE SE9500418A patent/SE507114C2/sv not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0702564B1 (en) | 2000-03-01 |
GB2285925A (en) | 1995-08-02 |
NO950421D0 (no) | 1995-02-06 |
DE4447677C2 (de) | 1998-07-23 |
AU676575B2 (en) | 1997-03-13 |
NO317148B1 (no) | 2004-08-30 |
NL9420005A (nl) | 1995-06-01 |
JP2911603B2 (ja) | 1999-06-23 |
WO1994028928A1 (en) | 1994-12-22 |
SE507114C2 (sv) | 1998-03-30 |
AT408445B (de) | 2001-11-26 |
AU6857194A (en) | 1995-01-03 |
CA2141871A1 (en) | 1994-12-22 |
SE9500418D0 (sv) | 1995-02-06 |
TW403655B (en) | 2000-09-01 |
CH687233A5 (de) | 1996-10-31 |
CA2141871C (en) | 1999-05-11 |
NL194910C (nl) | 2003-07-04 |
DE4493997C2 (de) | 1997-07-17 |
NO950421L (no) | 1995-04-07 |
ES2074968B1 (es) | 1996-05-01 |
SE9500418L (sv) | 1995-04-07 |
ES2074968A1 (es) | 1995-09-16 |
GB9502373D0 (en) | 1995-03-29 |
CN1112356A (zh) | 1995-11-22 |
GB2285925B (en) | 1997-04-09 |
RU2155226C2 (ru) | 2000-08-27 |
DE4493997T1 (de) | 1995-10-05 |
EP0702564A1 (en) | 1996-03-27 |
ATA900694A (de) | 2001-04-15 |
NL194910B (nl) | 2003-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2198405T3 (es) | Antigenos de superficie de tipo i asociados a staphylococcus epidermis. | |
Une et al. | Roles of V antigen in promoting virulence and immunity in yersiniae. | |
Kyd et al. | Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model | |
BRPI0316018B1 (pt) | vacina polissacarídica para infecções estafilocócicas | |
US5468484A (en) | Method of prevention of pseudomonas infection | |
JP4785014B2 (ja) | 蛋白質 | |
JPH09501826A (ja) | 新規な弱毒化シュードモナス・エルギノーザ株 | |
WO1998006432A1 (en) | Outer membrane protein b1 of moraxella catarrhalis | |
WO1992018162A1 (en) | Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use | |
US5861163A (en) | Process for preparing a vaccine against pseudomonas aeruginosa using attenuated strains | |
Boroff | STUDY ON TOXINS AND ANTIGENS OF SHIGELLA DYSENTERIAE I: Toxicity and Antigenicity of Whole Organisms and Various Fractions of Shigella dysenteriae | |
KR970001704B1 (ko) | 약독화 녹농균주 cfcpa 20215를 이용한 녹농균 감염 예방 백신 | |
KR970001703B1 (ko) | 약독화 녹농균주 cfcpa 10142를 이용한 녹농균 감염 예방 백신 | |
KR960014620B1 (ko) | 신규한 약독화 녹농균 및 그를 이용한 녹농균 감염 예방 백신 | |
KR970001707B1 (ko) | 약독화 녹농균주 cfcpa 50243을 이용한 녹농균 감염 예방 백신 | |
KR970001709B1 (ko) | 약독화 녹농균주 cfcpa 70018을 이용한 녹농균 감염 예방 백신 | |
JP2000509961A (ja) | 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体 | |
KR970001706B1 (ko) | 약독화 녹농균주 cfcpa 40057을 이용한 녹농균 감염 예방 백신 | |
KR970001708B1 (ko) | 약독화 녹농균주 cfcpa 60534를 이용한 녹농균 감염 예방 백신 | |
KR970001705B1 (ko) | 약독화 녹농균주 cfcpa 30720을 이용한 녹농균 감염 예방 백신 | |
US5223255A (en) | Bordetella pertussis variants | |
KR970001710B1 (ko) | 녹농균 감염증 치료제 및 그의 제조방법 | |
KR0180991B1 (ko) | 합성 펩티드를 함유하는 녹농균 백신 및 이것으로부터 생산된 치료제 | |
WO2004056851A1 (en) | Peptides mimicking vibrio cholerae o139 capsular polysaccharide and their use to elicit protective immune response | |
Cunningham | Molecular mimicry between streptococcal M protein and cardiac myosin and the immunopathogenesis of rheumatic fever |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090409 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090409 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100409 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110409 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120409 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130409 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140409 Year of fee payment: 15 |
|
LAPS | Cancellation because of no payment of annual fees |